Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.
Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.
复制标题
DOI：
10.3390/ijms140918899
复制
发表时间：
2013-09-13
影响因子：
5.6
通讯作者：
Tanaka E
中科院分区：
文献类型：
--
作者：
Kikuchi K;Tancharoen S;Ito T;Morimoto-Yamashita Y;Miura N;Kawahara K;Maruyama I;Murai Y;Tanaka E
中风是世界范围内死亡和残疾的主要原因。中风的主要原因是动脉粥样硬化，而动脉粥样硬化最常见的危险因素是高血压。因此，建议使用抗高血压治疗来预防卒中。三种血管紧张素受体阻滞剂（ARB），替米沙坦，厄贝沙坦和坎地沙坦，抑制晚期糖基化终末产物（AGEs）受体的表达，这是这些药物的多效性作用之一。高迁移率族蛋白1（HMGB 1）是脓毒症的配体，最近被鉴定为严重脓毒症的致死介质。HMGB 1是一种细胞内蛋白，当释放到细胞外环境中时充当炎性细胞因子。细胞外HMGB 1可导致多器官功能衰竭，并参与高血压、高脂血症、糖尿病、动脉粥样硬化、血栓形成和中风的发病机制。这是第一次文献综述，评价了三种ARB对HMGB 1-β轴治疗卒中的潜力，包括预防和急性治疗。本综述涵盖了1976年至2013年期间进行的临床和实验研究。我们认为，ARB抑制HMGB 1/HMGB 2轴，可能为预防和急性治疗卒中提供一种新的选择。然而，需要进行额外的临床研究来验证ARB的疗效。
Stroke is a major cause of mortality and disability worldwide. The main cause of stroke is atherosclerosis, and the most common risk factor for atherosclerosis is hypertension. Therefore, antihypertensive treatments are recommended for the prevention of stroke. Three angiotensin receptor blockers (ARBs), telmisartan, irbesartan and candesartan, inhibit the expression of the receptor for advanced glycation end-products (RAGE), which is one of the pleiotropic effects of these drugs. High mobility group box 1 (HMGB1) is the ligand of RAGE, and has been recently identified as a lethal mediator of severe sepsis. HMGB1 is an intracellular protein, which acts as an inflammatory cytokine when released into the extracellular milieu. Extracellular HMGB1 causes multiple organ failure and contributes to the pathogenesis of hypertension, hyperlipidemia, diabetes mellitus, atherosclerosis, thrombosis, and stroke. This is the first review of the literature evaluating the potential of three ARBs for the HMGB1-RAGE axis on stroke therapy, including prevention and acute treatment. This review covers clinical and experimental studies conducted between 1976 and 2013. We propose that ARBs, which inhibit the HMGB1/RAGE axis, may offer a novel option for prevention and acute treatment of stroke. However, additional clinical studies are necessary to verify the efficacy of ARBs.
登录
查看更多内容
DOI：
10.1186/cc10420
发表时间：
2011-08-26
期刊：
Critical care (London, England)
影响因子：
--
作者：
Arabi YM;Dehbi M;Rishu AH;Baturcam E;Kahoul SH;Brits RJ;Naidu B;Bouchama A
通讯作者：
Bouchama A
DOI：
10.1161/hypertensionaha.112.195511
发表时间：
2012-07
期刊：
Hypertension (Dallas, Tex. : 1979)
影响因子：
--
作者：
Carnevale D;Mascio G;D'Andrea I;Fardella V;Bell RD;Branchi I;Pallante F;Zlokovic B;Yan SS;Lembo G
通讯作者：
Lembo G
影响因子：
37.8
作者：
Cipollone, F;Iezzi, A;Mezzetti, A
通讯作者：
Mezzetti, A
影响因子：
5.4
作者：
Fukui, T;Rahman, M;Fukiyama, K
通讯作者：
Fukiyama, K
影响因子：
7.2
作者：
Grossin, N.;Wautier, M. -P.;Wautier, J. -L.
通讯作者：
Wautier, J. -L.